Protease Deficient Bacillus anthracis with Improved Recombinant Protein Yield Capabilities


Species of Bacillus, such as Bacillus anthracis, Bacillus cereus, and Bacillus subtilis, are attractive microorganisms for recombinant protein production in view of their fast growth rate, high yield, and ability to secrete produced products directly into the medium. Bacillus anthracis is also attractive in view of its ability to produce anthrax toxin and ability to fold proteins correctly. This application claims a B. anthracis strain in which more than one secreted protease is inactivated by genetic modification. Such a protease-deficient B. anthracis has an improved ability to produce recombinant secreted proteins compared to other bacteria, particularly other Bacillus. Improvements include production of intact (i.e., mature full-length) proteins, often at high yield.

Potential Commercial Applications: Competitive Advantages:
  • Vaccine production
  • Recombinant protein production
  • B. anthracis vaccine production
 
  • Highly efficient production of recombinant proteins
  • Low cost production of recombinant proteins


Development Stage:
  • Early-stage
  • In vitro data available


Inventors:

Andrei Pomerantsev (NIAID)  ➽ more inventions...

Stephen Leppla (NIAID)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 10,273,548 issued 2019-04-30
U.S. Pat: 9,555,064 issued 2017-01-31
US Application No. 61/514,384
US Application No. 61/521,617
US Application No. 14/236,430

Publications:
Pomerantsev A, et al. PMID 21827967

Collaboration Opportunity:

The NIAID is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize B. anthracis vaccines, B. anthracis protein production. For collaboration opportunities, please contact Charles Rainwater at 301-435-8617.


Licensing Contact:
Michael Piziali,
Email: pizialim@niaid.nih.gov
Phone: 301-496-2644

OTT Reference No: E-202-2011-0
Updated: Feb 25, 2015